Steven Silver
Stock Analyst at Argus Research
(3.85)
# 2,027
Out of 4,639 analysts
25
Total ratings
82.4%
Success rate
22.6%
Average return
Main Sectors:
Stocks Rated by Steven Silver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPCX Space Exploration Technologies | Upgraded: Buy | $160 | $133.29 | +20.04% | 2 | Aug 6, 2026 | |
| DXCM DexCom | Maintained: Buy | $90 → $96 | $89.53 | +7.23% | 3 | Aug 3, 2026 | |
| CVS CVS Health | Maintained: Buy | $90 → $104 | $93.50 | +11.23% | 4 | May 13, 2026 | |
| BAX Baxter International | Maintained: Hold | n/a | $27.61 | - | 4 | May 8, 2026 | |
| CAH Cardinal Health | Maintained: Buy | $189 → $248 | $240.26 | +3.22% | 4 | May 5, 2026 | |
| ITGR Integer Holdings | Downgraded: Hold | n/a | $125.04 | - | 2 | Oct 24, 2025 | |
| TZOO Travelzoo | Reiterated: Buy | $19 | $7.12 | n/a | 1 | May 11, 2022 | |
| THC Tenet Healthcare | Downgraded: Hold | n/a | $259.45 | n/a | 1 | Jun 13, 2014 | |
| ALNY Alnylam Pharmaceuticals | Rated: Buy | n/a | $221.20 | n/a | 2 | Jan 27, 2014 | |
| GILD Gilead Sciences | Maintained: Buy | $94 | $135.77 | n/a | 1 | Dec 9, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $12.55 | n/a | 1 | Oct 22, 2010 |
Space Exploration Technologies
Aug 6, 2026
Upgraded: Buy
Price Target: $160
Current: $133.29
Upside: +20.04%
DexCom
Aug 3, 2026
Maintained: Buy
Price Target: $90 → $96
Current: $89.53
Upside: +7.23%
CVS Health
May 13, 2026
Maintained: Buy
Price Target: $90 → $104
Current: $93.50
Upside: +11.23%
Baxter International
May 8, 2026
Maintained: Hold
Price Target: n/a
Current: $27.61
Upside: -
Cardinal Health
May 5, 2026
Maintained: Buy
Price Target: $189 → $248
Current: $240.26
Upside: +3.22%
Integer Holdings
Oct 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $125.04
Upside: -
Travelzoo
May 11, 2022
Reiterated: Buy
Price Target: $19
Current: $7.12
Upside: n/a
Tenet Healthcare
Jun 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $259.45
Upside: n/a
Alnylam Pharmaceuticals
Jan 27, 2014
Rated: Buy
Price Target: n/a
Current: $221.20
Upside: n/a
Gilead Sciences
Dec 9, 2013
Maintained: Buy
Price Target: $94
Current: $135.77
Upside: n/a
Oct 22, 2010
Maintained: Buy
Price Target: n/a
Current: $12.55
Upside: n/a